 MENLO PARK, Calif.BUSINESS WIRESummit Therapeutics Inc. NASDAQ: SMMT Summit, we, or the Company today announced that we have completed the closing of our previously announced definitive agreement with Akeso Inc. HKEX Code: 9926.HK, Akeso to in-license its breakthrough bispecific antibody, ivonescimab. Ivonescimab, known as AK112 in China and Australia, and as SMT112 in the United ...... 